Latest Revenue Growth News

Bravura Solutions has delivered a robust first half of FY26, posting nearly 10% revenue growth and a significant jump in profitability, while rewarding shareholders with a special dividend. The company also upgraded its full-year guidance, signalling confidence in its growth trajectory.

Bravura Solutions reports robust half-year growth with nearly 10% revenue increase, a fresh leadership appointment, and strategic expansion into the UK pensions market.

Bravura Solutions reported a solid 9.8% increase in underlying revenue for the half-year ending December 2025, despite the absence of prior non-recurring licence sale income. The company also announced a new CEO appointment and declared both interim and special dividends.

Kelly Partners Group Holdings Limited has reported a robust 17% increase in revenue for the first half of 2026, driven by strategic acquisitions and expanding international operations, particularly in the US.

Kelly Partners Group Holdings Limited reported a 17% rise in revenue for the half-year to December 2025, while statutory profit fell 15.5% due to acquisition costs and higher amortisation. Underlying earnings showed solid growth, reflecting the firm's core business strength.

Evolution Mining has reported a record half-year profit, with statutory net income more than doubling to $766.6 million, driven by higher gold and copper prices. The company also declared a fully franked interim dividend of 20 cents per share and progressed key mine expansions and developments.

Centuria Industrial REIT has reported a strong first half for 2025, with total revenue surging over 20% and net profit rising by 10%, while distributions remain steady.

National Storage REIT reported a 10.8% rise in revenue for the half year ended December 2025, while profit after tax fell 16.2%. The REIT declared a fully franked interim dividend of 6 cents per security.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.